1/15
Vocabulary practice flashcards covering definition criteria, etiology, maternal-fetal risks, clinical features, dosing guidelines, and management protocols for thyroid disorders during pregnancy.
Overt Hypothyroidism
A clinical condition defined biochemically by an elevated thyroid-stimulating hormone level (↑TSH) combined with a low free thyroxine level (Low FT4).
Hashimoto's Thyroiditis
An autoimmune disorder identified as the leading cause of primary hypothyroidism, marked by positive thyroid peroxidase (TPO-Ab) and thyroglobulin (TG-Ab) antibodies.
Subclinical Hypothyroidism (SCH)
A condition defined biochemically by elevated levels of TSH between 2.5mU/L and 10mU/L alongside normal circulating concentrations of free thyroxine (FT4).
Isolated Hypothyroxinaemia (IH)
A state characterized by normal TSH levels but low FT4 levels, defined as either below the reference range or between the 2.5th and 10th centile of the normal pregnant population.
Target TSH in Pregnancy
The biochemical therapeutic goal of achieving TSH≤2.5mU/L (or <2.5mU/L) with normal FT4 levels prior to conception and throughout antenatal care by titrating levothyroxine.
Empiric Levothyroxine Adjustment upon Pregnancy Confirmation
An immediate empiric dose escalation of approximately 25% upon confirmation of pregnancy, achieved by doubling the daily dose 2days per week, or increasing daily intake by 25μg/day (if baseline dose ≤100μg) or 50μg/day (if baseline dose >100μg).
Initial Levothyroxine Dose for Overt Hypothyroidism
The recommended full replacement starting dose for pregnant patients newly diagnosed with overt hypothyroidism, calculated as 1.6μg/kg/day.
Initial Levothyroxine Dose for Subclinical Hypothyroidism (ETA)
The starting dosage recommended by the European Thyroid Association for newly diagnosed subclinical hypothyroidism in pregnancy, calculated as 1.2μg/kg/day with a target TSH<2.5mU/L.
Antenatal Thyroid Monitoring Protocol
The clinical monitoring schedule requiring baseline TSH and FT4 assessment, follow-up testing every 4−6weeks until 20weeks of gestation, and a subsequent check at 28weeks.
Postpartum Medication Management (Pre-existing Hypothyroidism)
The protocol directing that maternal levothyroxine dosages increased during gestation should be returned to pre-pregnancy baseline levels at 2weeks postpartum.
Postpartum Medication Management (Gestational Diagnosis)
The protocol directing that women first prescribed levothyroxine during pregnancy discontinue treatment postpartum and obtain thyroid function tests (TFT) at 6weeks after delivery.
Thyroid Peroxidase Antibodies (TPO-Ab)
Autoantibodies directed against thyroid peroxidase; when present, they indicate a higher risk of gestational complications and necessitate vigilant postpartum monitoring for postpartum thyroiditis.
Maternal Complications of Hypothyroidism
Adverse maternal outcomes associated with untreated disease, including subfertility secondary to anovulation, cardiac dysfunction, pregnancy-induced hypertension (PIH), gestational diabetes, placental abruption, and preterm delivery.
Fetal and Neonatal Complications of Hypothyroidism
Adverse offspring risks including intrauterine growth restriction (IUGR), intrauterine fetal demise (IUFD), miscarriage, increased neonatal death, NICU admission, neonatal hypothyroidism, and low IQ due to insufficient T4 essential for fetal neurodevelopment.
Overt Thyrotoxicosis in Pregnancy
A condition occurring in 0.2%−0.4% of pregnant women, characterized biochemically by suppressed TSH levels and elevated FT4 levels outside the pregnancy-specific reference range.
Graves' Disease in Pregnancy
An autoimmune hyperthyroid condition representing the most frequent cause of gestational thyrotoxicosis, occurring with a prevalence of 0.2% during pregnancy.